Vision
  History
  Patient Focus
  Management
  Board of Directors
  Corporate Policies/Governance
  Contact DURECT
  Driving Directions


According to the CDC, cardiovascular disease, cancer, diabetes and other chronic diseases claimed the lives of more than 3.2 million Americans in 2005.





DURECT Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER® Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the ORADURŪ sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the TRANSDURŪ transdermal patch technology, the DURIN® Biodegradable Implant (drug-loaded implant system) and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has seven disclosed on-going development programs of which six are in collaboration with pharmaceutical partners.

DURECT’s strategy is to capitalize on the wealth of opportunities afforded by our proprietary platform technologies in three ways:

To internally develop promising products based on our technologies
To partner some of our product opportunities with development and/or commercialization partners at appropriate stages along the development timelines; and
To make our technologies, along with our pre-clinical and clinical development expertise available to partners with the desire to develop proprietary extended or controlled release formulations of a wide range of molecules.

The statements within the DURECT Corporation website, and affiliated websites, relating to DURECT's products in development, technology attributes or capabilities, product development plans, development timelines, expected product or technology benefits or potential product markets involve risks and uncertainties that could cause actual results to differ materially from those in such forward looking statements. Potential risks and uncertainties include, but are not limited to, our ability to develop and commercialize our products, our ability to complete successful clinical trials, our ability to obtain product approvals from regulatory agencies, marketplace acceptance of our products, our ability to successfully manufacture our products, our reliance on sole or limited suppliers, our ability to obtain adequate reimbursement from third-party payors and the introduction of competitive products by other companies, our ability to gain access to proprietary technology and drugs, our ability to enter into development or commercialization agreements with other life sciences companies, our ability to manage our growth and costs and relationships with third parties and finance our activities and operations. Further information regarding these and other risks is included in the company's S-1 registration statement, quarterly reports on Form 10-Q and annual report on Form 10-K, as filed with the SEC. Copies of these documents are available on request from the Investor Relations Department of DURECT.

NOTE: POSIDUR™, SABER®, TRANSDURŪ, ORADURŪ, ELADUR™, DURIN®, MICRODUR™, ALZET® and LACTEL® are trademarks of DURECT Corporation. Other trademarks referred to belong to their respective owners.



 
 © 2000-2014 DURECT Corporation
Last updated: November 14, 2014
Search     Contact     Site Index     Legal Notice     Privacy Policy